Skip to main content
. 1999 Aug;73(8):6729–6742. doi: 10.1128/jvi.73.8.6729-6742.1999

FIG. 2.

FIG. 2

FIG. 2

FIG. 2

Peak systemic anti-Ad5 neutralizing antibody levels as a function of dose and frequency of administration. E1− Ad vectors were administered by different routes to different groups of individuals as indicated. Each symbol represents a different individual. For convenience in plotting the data, only the log dose is given; for the actual doses (e.g., 8 × 107− instead of 107 in panel A), see Table 2. (A) Single intradermal administration of the AdGVCD.10 vector to normal individuals; (B) repeat administration (q3mo × 3) of the AdGVCFTR.10 vector to the airway epithelium of individuals with cystic fibrosis; (C) repeat administration (q15d × 4) of the AdGVCFTR.10 vector to the airway epithelium of individuals with CF; (D) repeat administrations (q7d × 2) of the AdGVCD.10 vector directly to liver metastasis of individuals with colon carcinoma; (E) single direct myocardial administration of the AdGVVEGF.121.10 vector to individuals with diffuse coronary artery disease. In all panels, the dashed horizontal line represents the lower limit of detection of the assay. For panels B and C, the timing of the repetitive doses are indicated on the abscissa.